Recombinant human megakaryocyte growth and development factor (MGDF) increases the numbers of megakaryocyte progenitor cells to normal values in long-term bone marrow cultures of patients with AML in first remission.
De Wynter, Erika A
Dexter, T Michael
Ryder, W David J
Testa, Nydia G
AffiliationCancer Research Campaign Department of Experimental Haematology, Paterson Institute for Cancer Research, Manchester, UK.
MetadataShow full item record
AbstractThe megakaryopoietic potential in the bone marrow (BM) of patients in first remission after treatment for acute myelogenous leukaemia (AML) was investigated using long-term bone marrow cultures (LTC) stimulated with megakaryocyte growth and development factor (MGDF). The baseline number of megakaryocyte colony-forming cells (Meg-CFC) was very low. However, there was a 10 to 100-fold increase of Meg-CFC in cultures treated with 10 ng/ml MGDF with mean numbers within the normal range for the first 4 weeks of culture with a 24-fold increase in their cumulative numbers. Similarly, a 12-fold increase in the numbers of megakaryocytes (MKs) was found by CD61 immunostaining. These effects were lost at the dose of 100 ng/ml. In contrast, the cumulative mean numbers of Meg-CFC in the control cultures from normal bone marrow (NBM) were not significantly different from those in cultures treated with 10 or 100 ng/ml MGDF. These results demonstrate that MGDF stimulates megakaryocytopoiesis in patients with AML in first remission, restoring the Meg-CFC compartment to normal values, a result with potential clinical implications for their treatment with autologous transplantation.
CitationRecombinant human megakaryocyte growth and development factor (MGDF) increases the numbers of megakaryocyte progenitor cells to normal values in long-term bone marrow cultures of patients with AML in first remission. 1998, 12 (6):907-11 Leukemia
- Ex vivo expansion of megakaryocyte progenitors: effect of various growth factor combinations on CD34+ progenitor cells from bone marrow and G-CSF-mobilized peripheral blood.
- Authors: Gehling UM, Ryder JW, Hogan CJ, Hami L, McNiece I, Franklin W, Williams S, Helm K, King J, Shpall EJ
- Issue date: 1997 Oct
- Comparison of megakaryopoiesis in vitro of paired peripheral blood progenitor cells and bone marrow harvested during remission in patients with acute myeloid leukaemia.
- Authors: Briggs M, Adams JA, Brereton ML, Burgess R, Hyde K, Lenehan H, Yin JA
- Issue date: 2001 Dec
- Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates.
- Authors: Harker LA, Hunt P, Marzec UM, Kelly AB, Tomer A, Hanson SR, Stead RB
- Issue date: 1996 Mar 1
- The in vitro effect of pegylated recombinant human megakaryocyte growth and development factor (PEG rHuMGDF) on megakaryopoiesis in normal subjects and patients with myelodysplasia and acute myeloid leukaemia.
- Authors: Adams JA, Liu Yin JA, Brereton ML, Briggs M, Burgess R, Hyde K
- Issue date: 1997 Oct
- Multilineage mobilization of peripheral blood progenitor cells in humans following administration of PEG-rHuMGDF.
- Authors: Rasko JE, Basser RL, Boyd J, Mansfield R, O'Malley CJ, Hussein S, Berndt MC, Clarke K, O'Byrne J, Sheridan WP, Grigg AP, Begley CG
- Issue date: 1997 Jun